Medicilon Logo
search icon search icon language icon contact icon menu icon
Medicilon Logo
search icon close search icon language icon contact icon menu icon
Contact Us
Close Button
Back To Top
Online Message×
Click switch
Close Button
Medicilon's News information
News information

Medicilon´s IND Filing-Innovative Drug Research and Development

Page View:

On December 9-10, 2019, the “Fifth Pharmaceutical Frontier Summit Forum” was held concurrently during the “Nanjing International Life and Health Technology Expo”, with the theme of “Leading Life Science and Technology, Empowering the Health Industry”, through academician reports and round tables Dialogues, special exchanges, exhibitions and other ways to gather innovative resources, focus on the frontiers of strategy, talk to top experts, share investment opportunities, integrate global resources, and promote the innovative development of my country’s biomedical industry.

Among them, the roundtable session invited Dr. Chunlin Chen, the founder & CEO of Medicilon, to participate in the discussion and discuss the “Golden Decade” of innovative drug research and development & international cooperation.

The discussion site of the round table forum of the 5th Pharmaceutical Frontier Summit

Roundtable discussion site

At the forum, Dr. Chunlin Chen shared the main service content of Medicilon Biologics in the past ten years: first, to leverage on the good development of China’s innovative drug research and development to vigorously develop domestic business; second, to adhere to the policy of dual reporting of innovative drugs during registration and application. Helped many domestic enterprises to obtain foreign clinical trial approvals. Dr. Chen hopes that companies can strengthen international cooperation, insist on opening to the outside world, gain international recognition, and pay attention to both scientific and international development.

Dr. Chunlin Chen, Founder & CEO of Shanghai Medicilon

Shanghai Medicilon is committed to the research and development of innovative drugs. Since 2015, the company has participated in the completion of more than 60 new drug and generic drug projects that have been approved by China CFDA/NMPA, US FDA, and Australian TGA to enter Phase I clinical trials. . In the future, Medicilon looks forward to helping more innovative drug R&D projects and contributing more strength to the early entry of new drugs into the clinical stage!

Medicilon’s innovative drug R&D platform:

Medicilon’s business scope:

Medicilon business scope

contact us
Tel: +86 (21) 5859-1500

Related Articles:

API process development of the new drug IND stage

Medicilon’s IND Application  Platform

IND Enabling Studies FDA

Medicilon successfully held CFDA IND seminar in Seoul, South Korea

Medicilon sponsored the seminar on new drug preclinical research and IND application strategy

IND Filing

Relevant newsRelevant news